Overview

• Cofepris authorized Pfizer’s updated COVID-19 vaccine for commercial use in Mexico during the 2025–2026 winter campaign, formulated against the LP.8.1 variant.
• Cofepris also approved Moderna’s updated vaccine directed at LP.8.1, with use authorized from six months of age for the upcoming campaign.
• The vaccine updates follow recommendations from the EMA and WHO issued in mid‑2025 to match prevailing SARS‑CoV‑2 lineages.
• Health guidance prioritizes updated boosters for adults 65 and older, people with moderate or severe immunosuppression, children under five, individuals with comorbidities such as cardiovascular disease or obesity, and pregnant women.
• SISVER reports 5,998 confirmed COVID-19 cases in 2025 through epidemiological week 33—about 52% fewer than the same period in 2024—while genomic surveillance showed LP.8.1 dominance in February–April and no detection of NB.1.8.1 in Mexico.